Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX0E03 for disability after ischemic stroke
NCT03629275Phase 2Terminated
- Sponsor
- ReNeuron
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
A Phase 2 trial of CTX0E03 DP in ischemic stroke, sponsored by ReNeuron. Started Aug 2018; status: terminated.
02
Drugs
CTX0E03 DP
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03629275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03629275.